Daphne L. Farrington

An Affinity Capture Elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug

James S. Bourdage, Carolyn A. Cook, Daphne L. Farrington et al. · Journal of Immunological Methods · 2007 · 151 citations

Anti-drug Antibody, Medicine, Bioanalysis +11

A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer

Amita Patnaik, Paul Haluska, Anthony W. Tolcher et al. · Clinical Cancer Research · 2015 · 137 citations

A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin

Jhanelle E. Gray, Jeffrey R. Infante, Les Brail et al. · Investigational New Drugs · 2015 · 70 citations

Molecular Pharmacology, Intravenous Ly2090314, Glycogen Synthase +8

TGF-β signalling-related markers in cancer patients with bone metastasis

José Baselga, Mace L. Rothenberg, Josep Tabernero et al. · Biomarkers · 2008 · 66 citations

A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer

Ignace Vergote, Florian Heitz, Paul Buderath et al. · Gynecologic Oncology · 2019 · 58 citations

Medicine, Pharmacology, Gynecology +7